Decreased serum level and increased urinary excretion of vascular endothelial growth factor-C in patients with chronic kidney disease.
- Author:
Sun Hee KIM
1
;
Yu Jin JUNG
;
Kyung Pyo KANG
;
Sik LEE
;
Sung Kwang PARK
;
Ju Hyung LEE
;
Nam Ho KIM
;
Won KIM
Author Information
1. Department of Internal Medicine and Research Institute of Clinical Medicine of Chonbuk National University-Chonbuk National University Hospital, Chonbuk National University Medical School, Jeonju, Korea. kwon@jbnu.ac.kr
- Publication Type:Original Article
- Keywords:
Chronic kidney disease;
Hemodialysis;
Hypertension;
VEGF-C
- MeSH:
Blood Pressure;
Diet;
Enzyme-Linked Immunosorbent Assay;
Glomerular Filtration Rate;
Humans;
Hypertension;
Prehypertension;
Renal Dialysis;
Renal Insufficiency, Chronic;
Vascular Endothelial Growth Factor C
- From:Kidney Research and Clinical Practice
2013;32(2):66-71
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Interstitial tonicity increases vascular endothelial growth factor-C (VEGF-C), a lymphangiogenic factor in salt-induced hypertension. Therefore, it can be assumed that changes of serum VEGF-C level may be associated with increasing blood pressure. However, there is no report about the changes of serum VEGF-C levels in patients with chronic kidney disease (CKD). The aims of this study were to investigate the changes of serum and urine VEGF-C levels in patients with CKD stage 3-4 and to evaluate the relationship between blood pressure and serum VEGF-C levels in the patients with CKD stage 5 and hemodialysis. METHODS: Glomerular filtration rate (GFR) was assessed by the Modification of Diet in Renal Disease equation. Blood pressure and VEGF-C levels (serum and urine) were measured by enzyme-linked immunosorbent assay (ELISA) in nine patients with stage 3-4 CKD, 41 hemodialysis patients, and eight healthy individuals. RESULTS: The median serum level of VEGF-C in patients with stage 3-4 CKD and stage 5 hemodialysis significantly decreased in comparison with healthy individuals. Urinary VEGF-C excretion increased in patients with stage 3-4 CKD compared with healthy control patients. For 41 hemodialysis patients, the serum level of VEGF-C in patients with stage 1 or stage 2 hypertension with hemodialysis did not significantly increase when compared with prehypertension hemodialysis patients. CONCLUSION: We demonstrated that circulating levels of VEGF-C were decreased in patients with CKD, and the decrease of VEGF-C in patients with stage 3-4 CKD coincided with an increase in the urinary excretion of VEGF-C.
